2014 - NANETS https://nanets.net/abstracts-archive/2014?format=html Thu, 15 Feb 2018 18:22:17 -0500 en-GB hourly 1 C37 – Reappraisal of Lymphatic Mapping for Midgut Neuroendocrine Patients Undergoing Cytoreductive Surgery https://nanets.net/abstracts-archive/2014/335-c37-reappraisal-of-lymphatic-mapping-for-midgut-neuroendocrine-patients-undergoing-cytoreductive-surgery?format=html C37 – Reappraisal of Lymphatic Mapping for Midgut Neuroendocrine Patients Undergoing Cytoreductive Surgery Wang

]]> https://nanets.net/abstracts-archive/2014/335-c37-reappraisal-of-lymphatic-mapping-for-midgut-neuroendocrine-patients-undergoing-cytoreductive-surgery?format=html Wang

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 18:22:17 -0500 OT02 – Netter-1: First Pivotal Multicenter Phase III Study Evaluating 177 Lu-dotatate in Midgut Neuroendocrine Tumors https://nanets.net/abstracts-archive/2014/343-ot02-netter-1-first-pivotal-multicenter-phase-iii-study-evaluating-177-lu-dotatate-in-midgut-neuroendocrine-tumors?format=html OT02 – Netter-1: First Pivotal Multicenter Phase III Study Evaluating 177 Lu-dotatate in Midgut Neuroendocrine Tumors Sierra

]]> https://nanets.net/abstracts-archive/2014/343-ot02-netter-1-first-pivotal-multicenter-phase-iii-study-evaluating-177-lu-dotatate-in-midgut-neuroendocrine-tumors?format=html Sierra

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:23:24 -0500 O01 – Neuroendocrine tumor (NET) Impact on Quality of Life (QOL) Patient Experience From the First Global NET Patient Survey: A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals https://nanets.net/abstracts-archive/2014/342-o01-neuroendocrine-tumor-net-impact-on-quality-of-life-qol-i-patient-experience-from-the-first-global-net-patient-survey-a-collaboration-between-the-international-neuroendocrine-cancer-alliance-inca-and-novartis-pharmaceuticals?format=html O01 – Neuroendocrine tumor (NET) Impact on Quality of Life (QOL) Patient Experience From the First Global NET Patient Survey: A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals Goldstein

]]> https://nanets.net/abstracts-archive/2014/342-o01-neuroendocrine-tumor-net-impact-on-quality-of-life-qol-i-patient-experience-from-the-first-global-net-patient-survey-a-collaboration-between-the-international-neuroendocrine-cancer-alliance-inca-and-novartis-pharmaceuticals?format=html Goldstein

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:57 -0500 C43 – Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract https://nanets.net/abstracts-archive/2014/341-c43-clinical-and-immunohistochemical-features-of-high-grade-neuroendocrine-neoplasia-of-the-gastrointestinal-tract?format=html C43 – Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract Zemek

]]> https://nanets.net/abstracts-archive/2014/341-c43-clinical-and-immunohistochemical-features-of-high-grade-neuroendocrine-neoplasia-of-the-gastrointestinal-tract?format=html Zemek

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:22 -0500 C41 – Everolimus (EVE) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 Trial (RADIANT-3) https://nanets.net/abstracts-archive/2014/339-c41-everolimus-eve-for-the-treatment-of-advanced-pancreatic-neuroendocrine-tumors-pnet-final-overall-survival-os-results-of-a-randomized-double-blind-placebo-pbo-controlled-multicenter-phase-3-trial-radiant-3?format=html C41 – Everolimus (EVE) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 Trial (RADIANT-3) https://nanets.net/abstracts-archive/2014/339-c41-everolimus-eve-for-the-treatment-of-advanced-pancreatic-neuroendocrine-tumors-pnet-final-overall-survival-os-results-of-a-randomized-double-blind-placebo-pbo-controlled-multicenter-phase-3-trial-radiant-3?format=html support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:21 -0500 C42 – Early Recurrence of Carcinoid Valvulopathy After Valve Replacement https://nanets.net/abstracts-archive/2014/340-c42-early-recurrence-of-carcinoid-valvulopathy-after-valve-replacement?format=html C42 – Early Recurrence of Carcinoid Valvulopathy After Valve Replacement Zacks

]]> https://nanets.net/abstracts-archive/2014/340-c42-early-recurrence-of-carcinoid-valvulopathy-after-valve-replacement?format=html Zacks

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:21 -0500 C40 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET) https://nanets.net/abstracts-archive/2014/338-c40-phase-1-expansion-study-of-an-oral-torc1-torc2-inhibitor-cc-223-in-non-pancreatic-neuroendocrine-tumors-net?format=html C40 – Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET) Wolin

]]> https://nanets.net/abstracts-archive/2014/338-c40-phase-1-expansion-study-of-an-oral-torc1-torc2-inhibitor-cc-223-in-non-pancreatic-neuroendocrine-tumors-net?format=html Wolin

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:20 -0500 C39 – Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients who have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing https://nanets.net/abstracts-archive/2014/337-c39-telotristat-etiprate-in-a-subset-of-carcinoid-syndrome-patients-who-have-high-levels-of-urinary-5-hydroxyindoleacetic-acid-and-frequent-flushing?format=html C39 – Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients who have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing Wheeler

]]> https://nanets.net/abstracts-archive/2014/337-c39-telotristat-etiprate-in-a-subset-of-carcinoid-syndrome-patients-who-have-high-levels-of-urinary-5-hydroxyindoleacetic-acid-and-frequent-flushing?format=html Wheeler

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:19 -0500 C38 – Telotristat Etiprate (TE) in a Subset of Patients with Carcinoid Heart Disease Included in Two Phase 2 Trials for Carcinoid Syndrome https://nanets.net/abstracts-archive/2014/336-c38-telotristat-etiprate-te-in-a-subset-of-patients-with-carcinoid-heart-disease-included-in-two-phase-2-trials-for-carcinoid-syndrome?format=html C38 – Telotristat Etiprate (TE) in a Subset of Patients with Carcinoid Heart Disease Included in Two Phase 2 Trials for Carcinoid Syndrome Wheeler

]]> https://nanets.net/abstracts-archive/2014/336-c38-telotristat-etiprate-te-in-a-subset-of-patients-with-carcinoid-heart-disease-included-in-two-phase-2-trials-for-carcinoid-syndrome?format=html Wheeler

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:18 -0500 C35 – Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy – A Novel Approach in Treating Midgut Neuroendocrine Tumors https://nanets.net/abstracts-archive/2014/333-c35-adjuvant-intraoperative-post-dissection-tumor-bed-chemotherapy-a-a-novel-approach-in-treating-midgut-neuroendocrine-tumors?format=html C35 – Adjuvant Intraoperative Post-Dissection Tumor Bed Chemotherapy – A Novel Approach in Treating Midgut Neuroendocrine Tumors Wang

]]> https://nanets.net/abstracts-archive/2014/333-c35-adjuvant-intraoperative-post-dissection-tumor-bed-chemotherapy-a-a-novel-approach-in-treating-midgut-neuroendocrine-tumors?format=html Wang

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:16 -0500 C36 – In Vitro Chemotherapy Profiling of Well-Differentiated Midgut Neuroendocrine Tumors (NETs) Based on Individual Patient Tumor Biomarkers Analysis https://nanets.net/abstracts-archive/2014/334-c36-in-vitro-chemotherapy-profiling-of-well-differentiated-midgut-neuroendocrine-tumors-nets-based-on-individual-patient-tumor-biomarkers-analysis?format=html C36 – In Vitro Chemotherapy Profiling of Well-Differentiated Midgut Neuroendocrine Tumors (NETs) Based on Individual Patient Tumor Biomarkers Analysis Wang

]]> https://nanets.net/abstracts-archive/2014/334-c36-in-vitro-chemotherapy-profiling-of-well-differentiated-midgut-neuroendocrine-tumors-nets-based-on-individual-patient-tumor-biomarkers-analysis?format=html Wang

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:16 -0500 C34 – Preoperative Metyrosine Improves Cardiovascular Outcomes For Patients Undergoing Surgery For Pheochromocytoma and Paraganglioma https://nanets.net/abstracts-archive/2014/332-c34-preoperative-metyrosine-improves-cardiovascular-outcomes-for-patients-undergoing-surgery-for-pheochromocytoma-and-paraganglioma?format=html C34 – Preoperative Metyrosine Improves Cardiovascular Outcomes For Patients Undergoing Surgery For Pheochromocytoma and Paraganglioma Wachtel

]]> https://nanets.net/abstracts-archive/2014/332-c34-preoperative-metyrosine-improves-cardiovascular-outcomes-for-patients-undergoing-surgery-for-pheochromocytoma-and-paraganglioma?format=html Wachtel

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:15 -0500 C33 – The Healthcare and Economic Impact of Diarrhea on US Patients with Carcinoid Syndrome https://nanets.net/abstracts-archive/2014/331-c33-the-healthcare-and-economic-impact-of-diarrhea-on-us-patients-with-carcinoid-syndrome?format=html C33 – The Healthcare and Economic Impact of Diarrhea on US Patients with Carcinoid Syndrome Broder

]]> https://nanets.net/abstracts-archive/2014/331-c33-the-healthcare-and-economic-impact-of-diarrhea-on-us-patients-with-carcinoid-syndrome?format=html Broder

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:14 -0500 C32 – Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients https://nanets.net/abstracts-archive/2014/330-c32-real-world-first-line-treatment-patterns-among-us-carcinoid-syndrome-patients?format=html C32 – Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients Sun

]]> https://nanets.net/abstracts-archive/2014/330-c32-real-world-first-line-treatment-patterns-among-us-carcinoid-syndrome-patients?format=html Sun

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:13 -0500 C30 – Pancreastatin Predicts Survival in Neuroendocrine Tumors https://nanets.net/abstracts-archive/2014/328-c30-pancreastatin-predicts-survival-in-neuroendocrine-tumors?format=html C30 – Pancreastatin Predicts Survival in Neuroendocrine Tumors Sherman

]]> https://nanets.net/abstracts-archive/2014/328-c30-pancreastatin-predicts-survival-in-neuroendocrine-tumors?format=html Sherman

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:12 -0500 C31 – Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data https://nanets.net/abstracts-archive/2014/329-c31-efficacy-of-octreotide-long-acting-repeatable-oct-from-the-phase-iii-radiant-2-study-in-patients-with-advanced-neuroendocrine-tumors-net-a-post-hoc-analysis-of-the-placebo-pbo-arm-with-updated-survival-data?format=html C31 – Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data Strosberg

]]> https://nanets.net/abstracts-archive/2014/329-c31-efficacy-of-octreotide-long-acting-repeatable-oct-from-the-phase-iii-radiant-2-study-in-patients-with-advanced-neuroendocrine-tumors-net-a-post-hoc-analysis-of-the-placebo-pbo-arm-with-updated-survival-data?format=html Strosberg

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:12 -0500 C29 – Octreotide LAR Among Elderly Patients With Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data https://nanets.net/abstracts-archive/2014/327-c29-octreotide-lar-among-elderly-patients-with-neuroendocrine-tumors-a-survival-analysis-of-seer-medicare-data?format=html C29 – Octreotide LAR Among Elderly Patients With Neuroendocrine Tumors: A Survival Analysis of SEER-Medicare Data Shen

]]> https://nanets.net/abstracts-archive/2014/327-c29-octreotide-lar-among-elderly-patients-with-neuroendocrine-tumors-a-survival-analysis-of-seer-medicare-data?format=html Shen

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:11 -0500 C28 – Ki 67 and/or Mitotic Count in the Czech Neuroendocrine Tumour Registry https://nanets.net/abstracts-archive/2014/326-c28-ki-67-and-or-mitotic-count-in-the-czech-neuroendocrine-tumour-registry?format=html C28 – Ki 67 and/or Mitotic Count in the Czech Neuroendocrine Tumour Registry Sedlackova

]]> https://nanets.net/abstracts-archive/2014/326-c28-ki-67-and-or-mitotic-count-in-the-czech-neuroendocrine-tumour-registry?format=html Sedlackova

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:10 -0500 C27 – Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study https://nanets.net/abstracts-archive/2014/325-c27-treatment-satisfaction-symptom-control-and-quality-of-life-qol-with-lanreotide-autogel-depot-lan-in-neuroendocrine-tumor-net-patients-with-carcinoid-syndrome-cs-results-from-the-symnet-study?format=html C27 – Treatment Satisfaction, Symptom Control, and Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) in Neuroendocrine Tumor (NET) Patients with Carcinoid Syndrome (CS): Results From the SymNET Study Ruszniewski

]]> https://nanets.net/abstracts-archive/2014/325-c27-treatment-satisfaction-symptom-control-and-quality-of-life-qol-with-lanreotide-autogel-depot-lan-in-neuroendocrine-tumor-net-patients-with-carcinoid-syndrome-cs-results-from-the-symnet-study?format=html Ruszniewski

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:09 -0500 C26 – Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study https://nanets.net/abstracts-archive/2014/324-c26-quality-of-life-qol-with-lanreotide-autogel-depot-lan-vs-placebo-in-patients-with-enteropancreatic-neuroendocrine-tumors-results-from-the-clarinet-core-study?format=html C26 – Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study Ruszniewski

]]> https://nanets.net/abstracts-archive/2014/324-c26-quality-of-life-qol-with-lanreotide-autogel-depot-lan-vs-placebo-in-patients-with-enteropancreatic-neuroendocrine-tumors-results-from-the-clarinet-core-study?format=html Ruszniewski

]]> support@adgcommunications.com (Super User) 2014 Thu, 15 Feb 2018 13:22:08 -0500